Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial

NCT03173976 is registered in ClinicalTrials.gov with Mohammed Milhem as lead sponsor.

NCT NCT03173976
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03173976 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Anti-Osteoclast Therapy as Neoadjuvant in Treatment of Chondrosarcoma - Phase 1b Trial
Lead sponsor
Mohammed Milhem
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 18, 2017
Completion date
May 1, 2028
Enrollment
17 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

chondrosarcoma